Skip to main content
Oxidative Medicine and Cellular Longevity logoLink to Oxidative Medicine and Cellular Longevity
. 2009 Apr-Jun;2(2):107–109. doi: 10.4161/oxim.2.2.8162

Iron toxicity

New conditions continue to emerge

Eugene D Weinberg 1,
PMCID: PMC2763253  PMID: 20357933

Abstract

During the past half century, excessive/misplaced iron has been observed to be a risk factor for an increasing number and diversity of disease conditions. An extensive list of conditions and of the types of iron association were published in early 2008. Within the subsequent year, four additional disorders have been recognized to be enhanced by iron: aging muscle atrophy, viral replication, rosacea and pulmonary alveolar proteinosis. This paper adds new data and emphasis on these disorders as entities associated with increased iron load and toxicity.

Key words: aging muscle atrophy, iron, iron associated diseases, iron toxicity, pulmonary alveolar proteinosis, rosacea, viral replication


A review written early in 2008 contained an extensive list of diseases for which excessive and/or misplaced iron has been reported to be a causative or associated risk factor.1 The metal is toxic by catalyzing generation of hydroxyl radicals that intensify oxidative stress as well as by serving as a growth-essential nutrient for invading microbial and neoplasmic cells.

In the subsequent twelve months following submission of the manuscript, four additional conditions in which iron is toxic have been described: (a) intensification of aging muscle atrophy,2 (b) increased replication of human immunodeficiency virus (HIV) and hepatitis C virus (HCV),3 (c) enhancement of rosacea,4 and (d) augmentation of pulmonary alveolar proteinosis (PAP).5 In this paper, the previously published tables of iron-related conditions and of the types of iron association are expanded to include these four conditions.

In the report on muscle atrophy, non-heme iron levels in gastrocnemius muscle in male rats increased by 233% between six and thirty months of age.2 Abundance of mRNA transferrin receptor-1 decreased by 80%. In related research in the same laboratory, non-heme iron and RNA oxidation increased significantly with age in quadriceps-derived subsarcolemma mitochondria.6 In a third related study, in rats between 29 and 37 months of age, non-heme iron in gastrocnemius muscle increased by 200% with an accompanying significant increase in oxidized RNA7 These changes were associated with evidence of sarcopenia; that is, decreased muscle mass and grip.

Although iron is not a component of viruses, infected host cells apparently need the metal to synthesize viral particles. During the past several decades, it has become manifest that one of the dangers of excessive iron is its ability to favor animal viral infections.8 The importance of iron in HIV infection has received particular attention.9 The multi-faceted molecular sites of action of iron in synthesis of HIV, as well as of HCV, are now being compiled.3 Of special interest are indications that viruses can manipulate iron homeostasis so as to ensure their replication in host cells.

Rosacea is a common chronic light-sensitive inflammatory skin disease. In this inquiry, peroxide and antioxidant potential of serum as well as of skin cell ferritin were assayed.4 Serum peroxide levels were higher and total anti-oxidant potential was lower in patients than in healthy controls (p < 0.05). The number of ferritin positive cells was higher (p < 0.001) in patient samples especially in those with severe disease. Ultraviolet irradiation of skin plus skin cell iron accelerated development of photo-sensitization, photo- aging and skin cancer.10 It will be of interest to directly measure iron deposits in rosacea cells.

In the investigation on PAP, bronchoalveolar lavage samples of 20 patients were compared with those of 20 healthy volunteers.5 Concentrations of iron, transferrin, transferrin receptor, lactoferrin and ferritin were significantly elevated in PAP relative to healthy persons. In contrast, quantities of ascorbate, glutathione and urate were significantly depressed in PAP patients, indicative of antioxidant depletion. The results suggest an iron-catalyzed oxidative stress in the maintenance of PAP.

Similar alterations in pulmonary iron homeostasis have been observed in several other chronic lung diseases.11

The list of iron-associated diseases, whose compilation began 25 years ago,12 continues to grow (Tables 1 and 2). Recognition of the toxicity of iron is stimulating research efforts to develop iron chelator drugs that might be able to remove the metal from specific disease sites.13,14

Table 1.

Conditions for which excessive/misplaced iron can be a risk factor

Aging Infectious Ophthalmic
muscle atrophy bacterial, fungal & protozoan infections macular degeneration
Cardiovascular viral infections: HIV, HCV Orthopedic
atherosclerosis gout
cardiomyopathy Neurologic hemophilic
hypertension ALS synovitis
ischemic stroke Alzheimer osteoarthritis
venous leg ulcer depression osteoporosis
Friedreich ataxia
Dermal Huntington Otologic
porphyria multiple sclerosis aminoglycoside
cutanea tarda Parkinson toxicity
rosacea PKAN
prion disease Pediatric & Neonatal
Endocrine Down syndrome
diabetes Obstetric epilepsy
endometriosis neonatal sudden infant death
growth deficiency hemochromatosis
hypogonadism pre-eclampsia Pulmonary
hypothyroidism alveolar proteinosis
Oncologic cystic fibrosis
Hepatic breast ozone lung injury
cirrhosis colorectal pneumoconiosis
steatohepatitis esophageal Renal
viral hepatitis hepatic aminoglycoside &
Kaposi sarcoma vancomycin toxicity
leukemia
lung

Modifed from Table 3 (Weinberg et al.)1.

Table 2.

Association of iron with morbidity

  • Iron, by itself, has been observed to initiate the disease

    • cardiomyopathy

    • growth deficiency

    • hemophilic synovitis

    • hypogonadism

    • lung cancer

    • osteoporosis

    • pneumoconiosis

  • Iron can be a cofactor in promoting the disease

    • Alzheimer

    • atherosclerosis

    • bacterial infections

    • diabetes

    • endometriosis

    • esophageal adenocarcinoma

    • fungal & protozoan infections

    • gout

    • hepatoma

    • multiple sclerosis

    • osteoarthritis

    • oto- & renal toxicity

    • ozone lung injury

    • pulmonary alveolar proteinosis

    • viral infections

  • Iron deposits are observed in disease-associated tissue sites

    • basal ganglia in PKAN

    • hepatocytes in cirrhosis, steatohepatitis & viral

    • hepatitis

    • mitochondria in Friedreich ataxia

    • pulmonary secretions in cystic fibrosis

    • retina in macular degeneration

    • skin cells in rosacea

    • skeletal muscle in aging

    • substantia nigra in Parkinson

    • thyroid in hypothyroidism

  • Body iron loading is associated with above normal incidence of morbidity

    • ALS

    • breast cancer

    • colorectal cancer

    • depression

    • Down syndrome

    • epilepsy

    • hypertension

    • ischemic stroke

    • leukemia

    • pre-eclampsia

    • porphryia cutanea tarda

    • prion disease

    • sudden infant death syndrome

  • Maternal antibodies can impair fetal iron metabolism

    • fetal or neonatal death in neonatal hemochromatosis

Modified from Table 4 (Weinberg et al.)1.

Abbreviations

ALS

amyotrophic lateral sclerosis

HCV

hepatitis C virus

HIV

human immunodeficiency virus

PAP

pulmonary alveolar proteinosis

PKAN

pantothenate kinase-associated neurodegeneration

Footnotes

Previously published online as an Oxidative Medicine and Cellular Longevity E-publication: http://www.landesbioscience.com/journals/oximed/article/8162

References

  • 1.Weinberg ED, Miklossy J. Iron withholding: A defense against disease. J Alz Dis. 2008;13:451–463. doi: 10.3233/jad-2008-13409. [DOI] [PubMed] [Google Scholar]
  • 2.Hofer T, Marzetti E, Xu J, Seo AY, Gulec S, Knutson MD, et al. Increased iron content and RNA oxidative damage in skeletal muscle with aging and disease atrophy. Exp Geront. 2008;43:563–570. doi: 10.1016/j.exger.2008.02.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat Rev Microbiol. 2008;6:541–555. doi: 10.1038/nrmicro1930. [DOI] [PubMed] [Google Scholar]
  • 4.Tisma VS, Basta-Juzbasic A, Jaganjac M, Brcic L, Dobric I, Lipozencic J, et al. Oxidative stress and ferritin expresson in the skin of patients with rosacea. J Am Acad Dermatol. 2009;60:270–276. doi: 10.1016/j.jaad.2008.10.014. [DOI] [PubMed] [Google Scholar]
  • 5.Ghio AJ, Stoneheurner JG, Richards JH, Crissman KM, Roggli VL, Plantadosi CA, et al. Iron homeostasis and oxidative stress in idiopathic pulmonaryalveolar proteinosis. Respir Res. 2008;9:10. doi: 10.1186/1465-9921-9-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Seo AY, Xu J, Servais S, Hofer T, Marzetti E, Wohlgemuth SE, et al. Mitochondial iron accumulation with age and functional consequences. Aging Cell. 2008;7:706–716. doi: 10.1111/j.1474-9726.2008.00418.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Xu J, Knutson MD, Carter CS, Leeuwenburgh C. Iron accumulation with age, oxidative stress and functional decline. PLoS ONE. 2008;3:e2865. doi: 10.1371/journal.pone.0002865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Weinberg ED. Iron withholding: A defense against viral infections. BioMetals. 1999;9:393–399. doi: 10.1007/BF00140609. [DOI] [PubMed] [Google Scholar]
  • 9.Weinberg GA, Boelaert JR, Weinberg ED. Iron and HIV infection. In: Friis H, editor. Micronutrients and HIV Infection. FL: CRC Press Boca Raton; pp. 135–158. [Google Scholar]
  • 10.Kitazawa M, Iwasaki K. Reduction of ultraviolet light-induced oxidative stress by amino acid chelators. Biochim BiophysActa. 1999;1473:400–408. doi: 10.1016/s0304-4165(99)00203-2. [DOI] [PubMed] [Google Scholar]
  • 11.Ghio AJ. Disruption of iron homeostasis and lung disease. Biochim Biophys Acta (General Subjects) 2008 doi: 10.1016/j.bbagen.2008.11.004. e-pub. [DOI] [PubMed] [Google Scholar]
  • 12.Weinberg ED. Iron withholding: A defense against infection and neoplasia. Physiol Rev. 1984;64:65–102. doi: 10.1152/physrev.1984.64.1.65. [DOI] [PubMed] [Google Scholar]
  • 13.Tam TF, Leung-Toung R, Li W, Wang Y, Karimian K, Spino M. Iron chelator research: Past, present, future. Curr Medicinal Chem. 2003;10:983–995. doi: 10.2174/0929867033457593. [DOI] [PubMed] [Google Scholar]
  • 14.Hider RC, Ma Y, Molina-Holgado F, Gaeta A, Roy S. Iron chelation as a potential therapy for neurodegenerative disease. Biochem Soc Trans. 2008;36:1304–1308. doi: 10.1042/BST0361304. [DOI] [PubMed] [Google Scholar]

Articles from Oxidative Medicine and Cellular Longevity are provided here courtesy of Wiley

RESOURCES